FDA grants pri­or­i­ty re­view for Dupix­ent in COPD, sets June ap­proval de­ci­sion dead­line

Sanofi and Re­gen­eron’s megablock­buster Dupix­ent just got one step clos­er to a land­mark ap­proval.

The FDA has grant­ed a pri­or­i­ty re­view with a tar­get dead­line …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER